Allergy medication without antihistamine is an important consideration for patients who experience troublesome side effects, have contraindications, or find that antihistamines alone do not adequately control their symptoms. From intranasal corticosteroids and leukotriene receptor antagonists to mast cell stabilisers, allergen immunotherapy, and biologic therapies, there is a broad range of effective alternatives available through the NHS. This article explains who may benefit from non-antihistamine allergy treatments, how each option works, what the NHS recommends, and when to seek further medical advice — helping patients and clinicians make informed, personalised treatment decisions.

Why Some People Need Alternatives to Antihistamines

Antihistamines are among the most commonly used treatments for allergic conditions, but they are not suitable for everyone. Some individuals experience troublesome side effects — most notably sedation, dry mouth, urinary retention, and cognitive impairment — particularly with older, first-generation antihistamines such as chlorphenamine. Even newer, non-sedating antihistamines such as cetirizine or loratadine can occasionally cause unwanted effects in sensitive individuals.

The risks associated with antihistamines vary considerably depending on the specific agent, generation, and dose. Certain patient groups may need to use antihistamines with caution or avoid particular agents altogether. These include people with:

• Glaucoma (particularly angle-closure glaucoma), where the anticholinergic effects of first-generation antihistamines can raise intraocular pressure

• Benign prostatic hypertrophy, where urinary retention is a risk, especially with first-generation agents

• Epilepsy, as some antihistamines may lower the seizure threshold — individual SmPCs should be consulted

• Pregnancy or breastfeeding, where careful consideration is required; second-generation antihistamines such as loratadine or cetirizine are generally preferred if an antihistamine is needed, but patients should seek advice from their GP or midwife before use

• Drug interactions, particularly with CNS depressants or monoamine oxidase inhibitors (MAOIs)

For guidance on specific agents, the BNF and individual Summary of Product Characteristics (SmPC) documents, available via the Electronic Medicines Compendium (EMC), should be consulted.

Additionally, some people find that antihistamines do not provide adequate symptom control for their particular allergy type. Conditions such as allergic asthma, severe allergic rhinitis, or chronic urticaria may require a broader or more targeted therapeutic approach. Understanding that effective allergy medication without antihistamine options exists is important for both patients and clinicians, ensuring that no one is left without appropriate symptom management simply because one class of drug is unsuitable.

Types of Allergy Medication That Do Not Contain Antihistamines

There is a range of allergy medications available in the UK that do not contain antihistamines, spanning prescription-only medicines, pharmacy-available treatments, and specialist therapies. The most widely used categories include:

Corticosteroids (topical and intranasal) Intranasal corticosteroids such as fluticasone propionate and beclometasone dipropionate are available over the counter and on prescription. According to NICE Clinical Knowledge Summaries (CKS) for allergic rhinitis, intranasal corticosteroids are the recommended first-line treatment for moderate-to-severe or persistent symptoms, particularly where nasal congestion is prominent. Topical corticosteroids are also used for allergic skin conditions such as eczema and contact dermatitis. Systemic corticosteroids are not routinely recommended for allergic rhinitis or eczema due to their adverse-effect profile; short courses may occasionally be considered in selected severe cases under specialist advice.

Leukotriene receptor antagonists (LTRAs) Montelukast is a prescription-only LTRA licensed in the UK for allergic rhinitis and asthma. It works by blocking cysteinyl leukotriene receptors involved in the inflammatory cascade. Its role is considered particularly when asthma and allergic rhinitis coexist, or when other treatments are not tolerated or are insufficient.

Mast cell stabilisers Sodium cromoglicate is available as eye drops and nasal spray for allergic conjunctivitis and rhinitis. It is particularly useful in children and those who cannot tolerate other treatments.

Intranasal ipratropium bromide Intranasal ipratropium bromide is a prescription-only anticholinergic agent that can help manage troublesome watery rhinorrhoea when other treatments are insufficient. It does not address nasal congestion or sneezing. Cautions include glaucoma and urinary retention; the BNF and SmPC should be consulted.

Short-term decongestants Topical nasal decongestants (e.g., xylometazoline) and oral decongestants (e.g., pseudoephedrine) may provide short-term relief of nasal congestion. However, topical decongestants should not be used for more than seven days due to the risk of rebound congestion (rhinitis medicamentosa). Oral decongestants are contraindicated in patients with cardiovascular disease, hypertension, hyperthyroidism, and certain other conditions; pharmacist or GP advice should be sought before use.

Immunotherapy (allergen immunotherapy) Subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are disease-modifying treatments available through specialist NHS allergy services for conditions such as hay fever, insect venom allergy, and house dust mite allergy. Eligibility is subject to clinical criteria and local commissioning arrangements; referral to a specialist allergy service is required.

Biologics Omalizumab, a monoclonal antibody targeting free IgE, is approved by NICE (TA278, TA339) for severe persistent allergic asthma and chronic spontaneous urticaria. Dupilumab, which blocks the IL-4 receptor alpha subunit (IL-4Rα) thereby inhibiting IL-4 and IL-13 signalling, is approved by NICE (TA534) for severe atopic dermatitis, and has additional licensed indications including severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps (CRSwNP).

This breadth of options means that clinicians can tailor allergy management to each individual's needs, comorbidities, and preferences.

How These Treatments Work and What They Are Used For

Each class of non-antihistamine allergy medication works through a distinct mechanism, targeting different points in the allergic inflammatory pathway.

Corticosteroids reduce inflammation by binding to intracellular glucocorticoid receptors, suppressing the transcription of pro-inflammatory cytokines. Intranasal corticosteroids are particularly effective for nasal congestion, sneezing, and rhinorrhoea associated with allergic rhinitis — symptoms that antihistamines alone may not fully control. Topical corticosteroids applied to the skin reduce redness, itching, and swelling in eczema and contact dermatitis. For contact dermatitis, identification and avoidance of the causative allergen is also an essential part of management; patch testing via a dermatology or allergy service can help identify triggers.

Montelukast blocks cysteinyl leukotriene receptors (CysLT1), preventing leukotrienes — inflammatory mediators released by mast cells and eosinophils — from triggering bronchoconstriction, mucus secretion, and nasal congestion. It is particularly considered in patients with co-existing asthma and allergic rhinitis, or when intranasal corticosteroids or antihistamines are not tolerated or are insufficient. It should be noted that for nasal symptoms alone, montelukast is generally less effective than intranasal corticosteroids.

Sodium cromoglicate stabilises mast cell membranes, preventing degranulation and the subsequent release of histamine and other inflammatory mediators. Because it acts prophylactically rather than reactively, it must be used regularly before allergen exposure to be effective. It is commonly used for allergic conjunctivitis and mild allergic rhinitis.

Allergen immunotherapy works by gradually desensitising the immune system to a specific allergen through repeated, controlled exposure. Over time, this shifts the immune response away from the allergic (Th2-mediated) pathway, reducing both immediate and late-phase allergic reactions. It is the only treatment that can modify the underlying disease course rather than simply managing symptoms.

Omalizumab binds free IgE in the bloodstream, preventing it from attaching to mast cells and basophils and thereby reducing the allergic response at its source.

Dupilumab blocks the IL-4 receptor alpha subunit (IL-4Rα), inhibiting signalling by both IL-4 and IL-13 — key cytokines driving type 2 (allergic) inflammation. This mechanism underpins its efficacy across several conditions characterised by type 2 inflammation, including severe atopic dermatitis, severe asthma, and chronic rhinosinusitis with nasal polyps.

Getting the Right Treatment: NHS and GP Guidance

In the UK, the management of allergic conditions is guided primarily by NICE Clinical Knowledge Summaries (CKS), NICE guidelines, and NHS clinical pathways, alongside guidance from the British Society for Allergy and Clinical Immunology (BSACI).

For allergic rhinitis, NICE CKS recommends intranasal corticosteroids as the first-line treatment for moderate-to-severe or persistent symptoms, particularly when nasal congestion is a predominant feature. For mild or intermittent symptoms, an antihistamine or sodium cromoglicate may be appropriate. Where nasal congestion remains troublesome despite intranasal corticosteroids, saline nasal irrigation or, in selected cases, intranasal ipratropium bromide (for watery rhinorrhoea) may be considered. The routine combination of intranasal corticosteroids with sodium cromoglicate nasal spray is not standard UK practice.

For patients with allergic asthma, NICE guideline NG80 outlines a stepwise approach that includes inhaled corticosteroids, long-acting beta-agonists, and leukotriene receptor antagonists — none of which are antihistamines. Montelukast may be prescribed by a GP in line with NG80 and the individual SmPC, and is particularly considered when asthma and allergic rhinitis coexist.

Patients who do not respond adequately to standard treatments, or who have severe or complex allergies, should be referred to an NHS allergy clinic. Key indications for specialist referral, as outlined by BSACI, include: suspected or confirmed anaphylaxis; suspected drug, venom, or food allergy; diagnostic uncertainty; occupational allergy; refractory or severe allergic rhinitis; and chronic spontaneous urticaria not responding to standard therapy. Allergen immunotherapy and biologic therapies are initiated and monitored by specialist allergy or respiratory teams, subject to eligibility criteria and local commissioning arrangements.

Some non-antihistamine allergy treatments — such as intranasal corticosteroids and sodium cromoglicate eye drops — are available without prescription from a pharmacist. A community pharmacist can provide useful guidance on appropriate over-the-counter options and advise when a GP appointment is warranted.

Potential Side Effects and Safety Considerations

Whilst non-antihistamine allergy medications are generally well tolerated, each carries its own safety profile that patients and prescribers should be aware of.

Intranasal corticosteroids are associated with local side effects including nasal dryness, epistaxis (nosebleeds), and, rarely, nasal septal perforation with prolonged use. Systemic absorption is low at standard doses, but the lowest effective dose should be used, as advised in the SmPC and BNF. Long-term use at higher doses — particularly in children — warrants monitoring of growth, in line with BNF guidance.

Montelukast carries an important safety consideration: the MHRA issued a Drug Safety Update in 2019 highlighting neuropsychiatric side effects, including sleep disturbances, nightmares, anxiety, depression, and suicidal ideation. Patients and carers must be counselled about these risks before starting treatment, and the medication should be discontinued if neuropsychiatric symptoms emerge. Prescribers should refer to the current SmPC and the MHRA Drug Safety Update for full prescribing information.

Sodium cromoglicate has an excellent safety profile and is considered suitable for use in pregnancy and in children. Side effects are generally mild and localised, such as transient stinging or burning with eye drops.

Allergen immunotherapy carries a risk of allergic reactions, including anaphylaxis, particularly with subcutaneous administration. It must therefore be administered in a clinical setting with resuscitation facilities available, and patients are typically observed for at least 30 minutes post-injection.

Omalizumab is generally well tolerated but can cause injection-site reactions and, rarely, anaphylaxis. It is administered under specialist supervision.

Dupilumab may cause injection-site reactions, conjunctivitis or keratitis (particularly in patients with atopic dermatitis), and, uncommonly, eosinophilia. Patients with known helminth (parasitic worm) infections should be treated before starting dupilumab, as per the SmPC. Both biologics require specialist initiation and ongoing monitoring.

Patients should always inform their GP or specialist of all medications they are taking to avoid interactions and ensure safe prescribing. Suspected side effects from any medicine should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

When to Seek Further Medical Advice for Allergy Symptoms

Whilst many allergic conditions can be managed effectively with over-the-counter or GP-prescribed treatments, there are circumstances in which prompt medical attention is essential. Knowing when to escalate care is an important aspect of allergy self-management.

Contact your GP if:

• Your allergy symptoms are not adequately controlled despite using appropriate treatments

• You experience side effects from your current allergy medication, including any neuropsychiatric symptoms if taking montelukast

• Your symptoms are significantly affecting your quality of life, sleep, or ability to work or study

• You develop new symptoms that may suggest a different or additional allergic condition

• You are pregnant, planning to become pregnant, or breastfeeding and need to review your allergy management

Seek urgent medical attention or call 999 if you experience signs of anaphylaxis, which include:

• Sudden swelling of the throat, lips, or tongue

• Difficulty breathing or swallowing

• A rapid or weak pulse

• Dizziness, collapse, or loss of consciousness

• A widespread skin rash accompanied by any of the above

Anaphylaxis is a medical emergency. If you have been prescribed an adrenaline auto-injector (such as an EpiPen, Jext, or Emerade), use it immediately, then call 999. Lie down with your legs raised (unless breathing is difficult), and if symptoms do not improve after five minutes, administer a second dose if available. Stay with the patient until emergency help arrives.

For those with complex or poorly controlled allergies, a referral to an NHS allergy specialist can open access to advanced diagnostic testing — such as specific IgE blood tests or skin prick testing — and specialist treatments including immunotherapy. Early specialist involvement can significantly improve long-term outcomes and reduce the burden of allergic disease. Do not hesitate to advocate for a referral if your symptoms remain uncontrolled on standard treatments.

Frequently Asked Questions